CDX2 is a Drosophila caudal-related homeobox transcription factor that is important for the establishment and maintenance of intestinal epithelial cells. We have reported that CDX2 promotes tumorigenicity in a subset of human colorectal cancer cell lines. Here, we present evidence that CDX2 negatively regulates the welldocumented growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3). Specifically, CDX2 binds to the IGFBP-3 gene promoter and can repress IGFBP-3 transcription, protein expression and secretion. Furthermore, inhibition of IGFBP-3 partially rescues the decreased anchorage-independent growth phenotype observed in CDX2 knockout cells. These data demonstrate for the first time that (1) CDX2 can function as a transcriptional repressor, and (2) one mechanism by which CDX2 promotes anchorage-independent growth is by transcriptional repression of IGFBP-3.
Introduction
CDX2 is an intestine-specific, Drosophila caudal-related homeobox transcription factor that is important for the establishment and maintenance of intestinal epithelial cells (James et al., 1994) . Mice that are heterozygousnull for Cdx2 are at increased risk for colonic neoplasms (Chawengsaksophak et al., 1997; Aoki et al., 2003) .
These studies have implied that CDX2 is a putative tumor suppressor.
We recently disrupted CDX2 in the human colon cancer cell lines LOVO and SW48 using targeted homologous recombination (Dang et al., 2006) . To our surprise, we found that CDX2 mediates anchorageindependent growth and resistance to anoikis in this subset of colorectal cancer cells. This paradigm is supported by previous observations. For example, Cdx2 heterozygous-null mice are significantly smaller than their wild-type counterparts (Chawengsaksophak et al., 1997) and CDX2 is the transforming event in some models of leukemia and lymphoma (Heckman et al., 2000; Rawat et al., 2004) .
The direct mechanisms by which CDX2 promotes anchorage-independent growth in colorectal cancer are unknown. Here, we present evidence that CDX2 negatively regulates insulin-like growth factor binding protein-3 (IGFBP-3). IGFBP-3 is the most abundant insulin-like growth factor binding protein in human serum, and has been shown to inhibit cellular growth and induce anoikis (Baxter, 2001; Lee et al., 2002) . In this report, we demonstrate for the first time that CDX2 can function as a transcriptional repressor of IGFBP-3 to promote anchorage-independent growth.
Results

Disruption of CDX2 leads to upregulation of IGFBP-3
To identify novel CDX2 downstream target genes, we subjected anchorage-independent LOVO and LOVO CDX2À/À cells to global gene expression analyses using Affymetrix U133A GeneChip (Santa Clara, CA, USA). IGFBP-3 expression was increased B3-fold in LOVO CDX2À/À cells compared with LOVO cells (data not shown). IGFBP-3 was selected for further analyses for three reasons. First, IGFBP-3 induces anoikis. Hence, CDX2 inhibition of IGFBP-3 expression could be a novel mechanism by which CDX2 promotes anchorageindependent growth. Second, whereas increased levels of serum IGFBP-3 are thought to be protective against cancer, an inverse correlation between serum IGFBP-3 and colorectal cancer risk remains controversial (Renehan et al., 2004) . We wondered whether tissue-specific CDX2 might modulate local IGFBP-3 expression. Third, mouse Cdx2 was cloned through its regulation of the insulin promoter (German et al., 1994) . In the same vein, IGFBP-3 regulates the insulin-like growth factor (IGF) axis, an important signaling pathway for cellular energy balance, neoplastic transformation and progression (Pollak et al., 2004) . These compelling historical data led us to explore a putative link between CDX2 and IGFBP-3.
To validate the microarray results, we examined IGFBP-3 expression in LOVO and LOVO CDX2À/À cells. Under anchorage-independent conditions, IGFBP-3 mRNA and protein expression, and protein secretion were upregulated B2-3-fold in LOVO CDX2À/À compared with LOVO cells (Figure 1a-c) . We also sequenced the IGFBP-3 gene in LOVO cells and found no mutations (data not shown). Thus, disruption of CDX2 resulted in increased IGFBP-3 expression under anchorage-independent conditions. CDX2 binds to the IGFBP-3 promoter As CDX2 modulates the expression of IGFBP-3 transcripts, we next examined whether CDX2 affects the IGFBP-3 promoter (Cubbage et al., 1990) . Close examination of 2 kb of the 5 0 -flanking IGFBP-3 promoter, using the TFSEARCH engine (Heinemeyer et al., 1998) revealed four clusters of putative CDX2 consensus binding sites (TTTAY, with Y ¼ A or C (Krasinski et al., 2001, Figure 2a) . We labeled these putative CDX2-binding regions as A, B, C and D. To determine if CDX2 binds to any of these sites in vivo, we performed chromatin immunoprecipitation (CHIP) assays in LOVO cells. Chromatin was immunoprecipitated (IP) with CDX2 antibody and the eluted genomic DNA was subjected to polymerase chain reaction (PCR) with primers flanking regions A, B, C and D (Figure 2b ). If CDX2 bound to the putative binding region(s), then the corresponding primers would yield more PCR products in CDX2 IP compared with non-IP (Input) chromatin. We found no significant increases in PCR products for regions A, B or C in CDX2 IP compared with Input chromatin. Thus, CDX2 does not bind to regions A, B or C. In contrast, we found significantly increased PCR products for region D in CDX2 IP compared with Input chromatin. These data support that CDX2 binds to region D of the IGFBP-3 promoter. This region is located from nt À705 to nt À555 from initiation, and encompasses three putative CDX2-binding sites.
To characterize further CDX2 binding to the IGFBP-3 promoter, we performed CHIP assays on both LOVO and LOVO CDX2À/À cells ( Figure 2c ). Sheared LOVO and LOVO CDX2À/À chromatin were IP with anti-CDX2 or anti-RNA polymerase II (RNAPII) antibodies. RNA-PII is an integral component of mRNA transcription and binds to most active promoters, including the GAPDH gene promoter (Sims et al., 2004) . The chromatin was subjected to PCR with four different primer sets: Region D, MUC2 þ , MUC2À and GAPDH þ primers. As expected, reactions using Input DNA yielded products with all primers (lanes 3 and 6). Consistent with our results in Figure 2b , Region D primers amplified more products in LOVO chromatin enriched with CDX2 IP than Input (lane 1a vs 3a). Conversely, only a faint band was noted in LOVO CDX2À/À chromatin enriched with CDX2 IP (lane 4a). This faint band is likely nonspecific, as it was much lighter than Input (lane 6a). Incidentally, we noted that loss of CDX2 binding to region D of the IGFBP-3 promoter was associated with increased RNAPII binding to the same region. Region D primers amplified threefold more product from LOVO CDX2À/À chromatin that underwent RNAPII IP compared with Input (lanes 5a vs 6a). In contrast, Region D primers amplified twofold less products from LOVO chromatin that underwent RNA-PII IP compared with Input (lanes 2a vs 3a). As RNAPII predominantly binds to active promoter loci, this would suggest that there is more active transcription in region D of the IGFBP-3 promoter in LOVO CDX2À/À cells compared with LOVO cells, consistent with the hypothesis that CDX2 inhibits IGFBP-3 transcription. To validate these assays, we subjected the chromatin to PCR with primers for a known CDX2 transcription target. CDX2 is well-known to bind to and activate the 5 0 -flanking MUC2 promoter at nt À201 to nt À162 (Yamamoto et al., 2003) . Using MUC2 þ primers that flank this region, we found increased PCR products from LOVO chromatin that underwent CDX2 IP or RNAPII IP, compared with Input (lanes 1b and 2b vs 3b). In contrast, MUC2 þ primers amplified fewer products from LOVO CDX2À/À chromatin that underwent CDX2 IP or RNAPII IP, compared with Input (lanes 4b and 5b vs 6b). These results are consistent with reports that CDX2 binds to and transcriptionally activates this region of the MUC2 promoter (Yamamoto et al., 2003) . As expected, MUC2À primers, which flank regions outside the CDX2-binding site, did not amplify products from CDX2 IP when compared with Input chromatin (lanes 1-6c). As positive control, GAPDH þ primers yielded PCR product from chromatin that was enriched with RNAPII IP, in both cell lines (lanes 2d and 5d) . Conversely, chromatin that underwent CDX2 IP was not enriched for GAPDH þ primers products (lanes 1d and 4d). Collectively, these CHIP assays show that CDX2 binds to region D of the IGFBP-3 promoter. Furthermore, CDX2 binding is associated with decreased RNAPII binding at the same site, which suggests that CDX2 binding to region D of the IGFBP-3 promoter is associated with loss of active transcription.
CDX2 represses IGFBP-3 promoter activity
To determine if CDX2 functionally represses IGFBP-3 transcription, we measured IGFBP-3 promoter activity using dual-luciferase assays. The À732 bp fragment of the IGFBP-3 promoter, containing region D, was linked to a Firefly luciferase reporter and co-transfected with Renilla luciferase into LOVO and LOVO CDX2À/À cells (Figure 3a) . Indeed, À732 IGFBP-3-pGL3 promoter activity was increased B2-fold in LOVO CDX2À/À compared with LOVO cells. These findings support that CDX2 transcriptionally represses IGFBP-3 promoter activity. To determine the roles of the three putative CDX2-binding sites at region D, we performed 5 0 promoter deletion analyses with three additional reporter constructs. The À680 IGFBP-3-pGL3 construct had the first putative CDX2-binding site deleted. This had no effect on promoter activity in LOVO cells. The À605 IGFBP-3-pGL3 construct had the first and second CDX2-binding sites deleted. This resulted in equivalent promoter activities in LOVO and LOVO CDX2À/À cells. This would suggest that the second putative CDX2-binding site is important for repressing IGFBP-3 promoter activity. The À560 IGFBP-3-pGL3 construct had all three putative binding sites deleted, and also exhibited equivalent activity in LOVO and LOVO CDX2À/À cells. Thus, site 3 did not additionally contribute to transcriptional repression. Altogether, these data show that CDX2 requires at least the first two binding sites on region D to repress IGFBP-3 promoter activation, with site 2 being most important. To confirm our findings, we performed site-directed mutagenesis at sites 1 and 2. Mutation of either site 1 or 2 only partially restored promoter activity in LOVO compared with LOVO Figure 2a) ; the À680 construct contains sites 2 and 3; the À605 construct contains site 3 alone, and the À560 construct does not contain any sites. The À732 construct was also subjected to site-directed mutagenesis at site 1 (732D1), site 2 (732D2), or both sites 1 and 2 (732D1D2). Methods in Supplementary Data. sites 1 and 2 resulted in equivalent promoter activity in LOVO and LOVO CDX2À/À cells (À732D1D2). Thus, both sites 1 and 2 are required for CDX2 transcriptional repression of the IGFBP-3 promoter. To determine if our findings were generalizable, we measured activity of the same reporter constructs in two additional colorectal cancer cell lines that express CDX2, SW48 and LS174T (Figure 3b) . Again, we found that deletion of CDX2-binding sites 1 and/or 2 led to increased IGFBP-3 promoter activity in both cell lines. Taken together, these data support the conclusion that CDX2 binds to the IGFBP-3 promoter and represses IGFBP-3 transcription. This transcriptional repression is mediated by CDX2-binding sites at nt À694 and nt À676 from initiation. Although CDX2 has been shown to regulate negatively gene expression (Guo et al., 2004; Escaffit et al., 2006) , these are the first data to demonstrate that CDX2 can act as a transcriptional repressor. alter anchorage-dependent colony formation in either cell lines (data not shown). These data show that in LOVO cells, CDX2 promotion of anchorage-independent colony formation is partly and specifically mediated by repression of IGFBP-3.
We next determined whether CDX2 repression of IGFBP-3 specifically affected cellular response to IGF. IGFBP-3 binds and sequesters IGFs to inhibit cell growth. IGF signaling through IGF-1 and IGF-2 is well known to stimulate cellular proliferation and survival (Pollak et al., 2004) . We reasoned that as LOVO cells expressed less IGFBP-3, they would be more receptive to growth stimulation by IGF-1 than LOVO CDX2À/À cells. Conversely, Long IGF-1 (LIGF-1) is a form of IGF-1 that does not bind to IGFBP-3; thus both LOVO and LOVO CDX2À/À cells should be equally receptive to LIGF-1 (Francis et al., 1992) . We treated LOVO and LOVO CDX2À/À cells with IGF-1 and LIGF-1 ligands and measured ensuing anchorage-independent colony formation (Figure 4a ). Indeed, IGF-1 increased anchorageindependent colony formation in LOVO cells by B2-fold, but not in LOVO CDX2À/À cells. In contrast, LIGF-1 promoted anchorage-independent colony formation by B2-fold in both LOVO and LOVO CDX2À/À cells. Altogether, these data are consistent with a paradigm in which CDX2 represses IGFBP-3 expression, thus promoting IGF-1 bioavailability and anchorageindependent colony formation. partially explain the dual roles that CDX2 has on tumor growth. Perhaps under anchorage-dependent conditions, IGFBP-3 does not significantly contribute to tumor growth, thus CDX2 regulation of IGFBP-3 may not significantly contribute to the tumor phenotype. As such, the anti-proliferative effects of CDX2 are observed under anchorage-dependent conditions. Conversely, under anchorage-independent conditions, IGFBP-3 induces anoikis; thus the role of CDX2 in repressing IGFBP-3 becomes more significant, resulting in a growth-promoting CDX2 phenotype. The relevance of our observation to human colorectal cancer progression remains to be determined. We speculate that local reduction of secreted IGFBP-3 in CDX2-expressing tumor cells may enhance their growth. This might explain why serum IGFBP-3 levels are not consistently inversely correlated with colorectal cancer risk (Renehan et al., 2004) .
The mechanism by which CDX2 exerts a repressive influence on IGFBP-3 transcription is through binding to the IGFBP-3 promoter and transcriptional repression, mediated by consensus binding sites located at nt À694 and nt À676. Furthermore, CDX2 interferes with RNAPII binding to the IGFBP-3 promoter. Whether CDX2 interacts with RNAPII or one of its co-factors in the transcriptional complex remains unknown. Furthermore, the roles of additional CDX2-downstream genes remain to be explored. Certainly, further investigations are warranted and ongoing. Nevertheless, these are the first studies to demonstrate that CDX2 promotes anchorage-independent growth by transcriptional repression of IGFBP-3.
